Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Zegocractin · CM-4620

Small molecule · Inhibitor of calcium release-activated calcium channel protein 1 (Orai1) (ORAI1) · developed by CalciMedica

Phase 2 Most advanced trial
CALC Developer
5 Registered trials

What is Zegocractin?

Zegocractin (CM4620) is an inhibitor of the calcium release-activated calcium (CRAC) channel that binds Orai1, the pore-forming protein of the channel, blocking extracellular calcium entry into cells. It reduces calcium-mediated signaling and the release of inflammatory cytokines such as IL-2 and TNF-alpha. It has been studied in acute pancreatitis, systemic inflammatory response syndrome, and pneumonia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CM-4620, Auxora
Drug type
Small molecule
Targets
calcium release-activated calcium channel protein 1 (Orai1) (ORAI1)
Mechanism
Inhibitor of calcium release-activated calcium channel protein 1 (Orai1) (ORAI1)
Pathways
store-operated calcium entry (SOCE), calcium-mediated signaling and gene transcription, IL-2 and TNF-alpha release
Therapy area
Gastroenterology, Infectious disease, Respiratory
Developer
CalciMedica, Inc. (CALC)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
564AW1RR37

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04681066 Phase 2 Acute Pancreatitis Completed CALC
NCT04661540 Phase 2 Pneumonia Terminated CALC
NCT04195347 Phase 1/2 Acute Pancreatitis Recruiting CALC
NCT03709342 Phase 2 Acute Pancreatitis Completed CALC
NCT03401190 Phase 2 Acute Pancreatitis Completed CALC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute PancreatitisPneumoniaSystemic Inflammatory Response Syndrome

More from CalciMedica

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CALC page.

Follow CALC, the company behind Zegocractin

See CALC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CALC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.